Abbott Laboratories stock holds above $111 as new heart device wins CE mark
Published on 08/29/2026 at 10:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Abbott Laboratories (US0028241000) stock is trading in the low $110s in late August 2026, with a recent quote highlighting a level of $112.47 on August 29, 2026 and a prior official close at $111.46 on August 27, 2026 as investors digest a new European approval for the company’s Amulet 360 heart device and steady mid-single-digit sales growth.
Stock trades just above $111 with $193 billion value
According to a recent stock overview href='https://finance.yahoo.com/quote/ABT/' title='Abbott Laboratories stock quote overview'>a live quote on August 29, 2026 shows Abbott Laboratories changing hands at $112.53 during regular trading, up 0.94% on the day, signaling a modest positive tone in the shares at that time. A separate price history page href='https://www.marketbeat.com/stocks/NYSE/ABT/chart/' title='Abbott Laboratories stock price history overview'>reports that Abbott closed the prior completed session on August 27, 2026 at $111.46 with a daily decline of 2.31% and an accompanying market capitalization of $192.87 billion, highlighting how the stock is fluctuating in a relatively tight range while representing one of the larger names in global healthcare. The same data snapshot indicates a recent trading volume of 8.35 million shares on that August 27, 2026 close, giving investors a sense of the stock’s liquidity and reinforcing that the current price level a little above $111 comes with robust daily turnover.
For traders looking at short-term technical context, one trading-focused analysis href='https://news.stocktradersdaily.com/news_release/8/Precision_Trading_with_Abbott_Laboratories_ABT_Risk_Zones_082926011602_1787980562.html' title='Trading risk zones for Abbott Laboratories stock'>highlights a set of risk zones for Abbott Laboratories stock, listing thresholds at $79.01, $90.90, $102.95 and $112.47, with the bolded $112.47 corresponding to the current price level. That framework suggests that at the current price around $112 the stock is trading just above the $102.95 zone and testing the upper threshold of $112.47, which can be interpreted by some market participants as a nearby reference point for support and resistance in the short term. When combined with the August 27, 2026 close of $111.46, the data underscores that Abbott shares are hovering just under that upper risk zone while still well above the lower bands in the $79 to $90 range.
Recent quarter shows revenue growth and consensus upside
Recent coverage href='https://www.marketbeat.com/instant-alerts/filing-trust-co-of-vermont-takes-position-in-abbott-laboratories-abt-2026-08-28/' title='Institutional positioning and valuation metrics for Abbott Laboratories'>notes that Abbott Laboratories stock opened a recent session at $111.46 and that the company is currently followed by analysts with an overall Moderate Buy rating and an average target price of $119.50 per share. That consensus target sits roughly $8 above the late-August 2026 trading band around $111 to $112, framing an upside scenario of roughly 7% when comparing the current quote of $112.53 to the $119.50 target. The same summary points out that the firm continues to pay a quarterly dividend of $0.63 per share, translating into an annualized payout of $2.52 and a yield of 2.3% based on the stock price referenced in that report, giving income-focused investors a cash-return component on top of prospective capital appreciation.
While the latest detailed quarterly figures do not appear in this set of sources, the available reporting emphasizes that Abbott’s most recent financial results featured mid-single-digit revenue growth against the comparable prior-year period and continued profitability in its core medical devices and diagnostics operations, with the current consensus reflecting confidence that earnings can continue to grow from that base. In practice that means that analysts anticipate the company generating higher per-share earnings over the coming four quarters than it did in the last twelve months, supporting the Moderate Buy designation and the $119.50 average target cited in the same coverage. For investors, a key interpretive point is that the current trading zone just above $111 already prices in some of this expected growth, yet still leaves a modest spread to the consensus valuation band.
Amulet 360 heart device gains CE mark in Europe
A notable operational development for Abbott in late August 2026 is the European regulatory clearance for its next-generation Amulet 360 device for left atrial appendage closure. A detailed industry article href='https://www.medtechdive.com/news/abbott-wins-ce-mark-for-new-laa-closure-device/829072/' title='Coverage of Abbott Amulet 360 CE mark approval'>reports that the company has secured Europe’s CE mark for the Amulet 360, a new version of its Amulet implant designed to seal the heart’s left atrial appendage to help reduce stroke risk in people with atrial fibrillation. The same report notes that Amulet 360 met benchmarks for safety and effectiveness in the VERITAS study presented at the 2026 AF Symposium, giving the device a clinical foundation as Abbott prepares to roll it out across European markets.
The company indicated in that coverage that Amulet 360 has been engineered to improve how the implant conforms to and seals the left atrial appendage, which can potentially make procedures more efficient and outcomes more consistent versus earlier-generation devices. Abbott plans to expand use of the new device across European countries in the coming weeks as of August 28, 2026, pointing to a near-term commercial ramp that could contribute to its structural heart portfolio revenue over time. For investors, the key takeaway is that this CE mark provides a gateway into the European market for an upgraded product in a growing category where left atrial appendage closure devices are used to reduce stroke risk in patients who may not be ideal candidates for long-term anticoagulant therapy.
This regulatory milestone also provides an incremental growth lever in a business where Abbott is competing against other major medtech players in structural heart interventions. If Amulet 360 can capture share in Europe, especially given its improved design intended to enhance conformability and sealing, that performance could support the mid-single-digit revenue growth trajectory highlighted in recent coverage and help underpin analyst expectations for both top-line and earnings expansion. Aligning this product news with the stock-level data, the late-August 2026 trading range in the low $110s effectively embeds the market’s current assessment of how much revenue and profit contribution Amulet 360, and other pipeline products, can deliver over the next several years.
Partnerships expand Abbott’s diagnostics reach
Beyond cardiac devices, Abbott is also extending its diagnostics footprint through collaborations with smaller healthcare companies. A recent press release href='https://www.bnnbloomberg.ca/press-releases/2026/08/28/avricore-grants-options/' title='Announcement of collaboration involving Abbott point-of-care tests'>highlights that a healthcare platform provider has entered into a formal collaboration agreement to supply and distribute Abbott point-of-care testing products through a digital clinical platform in the United Kingdom. The announcement, dated August 20, 2026 and referenced again on August 28, 2026, underscores how Abbott leverages partnerships to broaden access to its testing solutions in community and pharmacy settings.
In this collaboration, the partner’s HealthTab platform integrates Abbott’s point-of-care devices, enabling pharmacies and clinics to perform rapid blood testing and share results in near real time with patients and clinicians. For Abbott, such arrangements can drive incremental demand for its diagnostics hardware and consumables without the company needing to build out its own end-user digital platform in every region. From an investor’s perspective, this strategy can be seen as a capital-efficient way to extend the revenue base in diagnostics, complementing the device-driven growth from launches such as Amulet 360 in structural heart care.
In combination, the CE-mark clearance for Amulet 360 and the expansion of point-of-care diagnostic partnerships illustrate how Abbott is working on both the device and diagnostics sides of its portfolio to support long-term growth. The key challenge for management will be converting these opportunities into sustained revenue contributions large enough to move the needle relative to a business with a market capitalization approaching $193 billion and a stock price trading just above $111 as of late August 2026.
FreeStyle Libre as a flagship glucose monitoring product
Among Abbott’s product lines, one of the most widely recognized offerings for investors and patients alike is its FreeStyle Libre family of continuous glucose monitoring systems. Recent commentary href='https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/how-investors-are-reacting-to-abbott-abt-dual-glucoseketone' title='Investor discussion of Abbott glucose and ketone monitoring innovations'>describes how Abbott discovers, develops, manufactures and sells healthcare products worldwide and emphasizes the company’s role in glucose monitoring innovations, including the evolution of dual glucose and ketone sensing technology. FreeStyle Libre has been a key driver of Abbott’s diabetes care segment, allowing users to monitor interstitial glucose levels continuously via a small wearable sensor paired with a reader or smartphone.
The FreeStyle Libre franchise generates recurring revenue from both the sensors and associated readers, making it a significant contributor to Abbott’s overall top line. Performance in this category has historically delivered double-digit sales growth in various periods as adoption increased globally, though the specific latest quarter figures are not detailed in the current set of sources. For investors evaluating Abbott stock, the combination of FreeStyle Libre’s established market position and the pipeline of innovations such as potential dual glucose and ketone monitoring underscores why the diabetes care business remains a central pillar in the company’s growth narrative alongside structural heart devices and diagnostics.
Stock price context and investor view
ABBott Laboratories stock currently trades on the New York Stock Exchange under the ticker ABT, with recent market data indicating a late-August 2026 live price of $112.53 as of 1:47 p.m. ET on August 29, 2026 and a prior close of $111.46 on August 27, 2026. At that prior close the company’s market capitalization was reported at $192.87 billion, reflecting investor willingness to assign a rich valuation multiple to a diversified healthcare group with leading positions in diagnostics, medical devices, nutrition and branded generics. The interplay between that valuation and the consensus target of $119.50 suggests that while the stock is not deeply discounted, analysts see room for moderate appreciation if Abbott executes on its growth initiatives in areas such as Amulet 360, FreeStyle Libre and point-of-care testing partnerships.
For long-term shareholders, the current setup combines a sizable dividend yielding just over 2% based on the referenced annual payout of $2.52 per share and the late-August 2026 share price, plus the potential for capital gains if earnings grow in line with expectations. With the stock trading just under the highlighted risk zone level of $112.47 and well above the lower risk thresholds in the $79 to $90 range, Abbott Laboratories stock offers a blend of defensive healthcare exposure and measured growth, anchored by a market capitalization close to $193 billion and supported by ongoing product and partnership developments.
Read more
More on Abbott Laboratories products and investor information
Continuous glucose monitoring as a growth driver
Abbott’s FreeStyle Libre system has transformed glucose monitoring for many patients by minimizing the need for fingerstick tests and enabling continuous tracking of glucose trends throughout the day and night. The system’s streamlined design, which combines a wearable sensor with a companion reader or smartphone app, reduces barriers to adoption and supports healthcare providers in optimizing diabetes treatment plans. As Abbott continues to innovate within this product line, including research into dual glucose and ketone sensing, the FreeStyle Libre franchise remains central to the company’s strategy to expand in the global diabetes care market.
Abbott stock price snapshot
As of August 29, 2026, Abbott Laboratories stock is referenced at an intraday price point of $112.53 during regular NYSE trading hours, compared with a most recent completed-session close of $111.46 on August 27, 2026, both in USD. That price level implies a market capitalization of $192.87 billion at the August 27, 2026 close, positioning Abbott firmly among the larger constituents of major healthcare and broad-market equity indices.
Fact box
Company: Abbott Laboratories
ISIN: US0028241000
Ticker: ABT
Exchange: NYSE
Price (as of August 29, 2026, 1:47 p.m. ET): $112.53 USD
Market cap: $192.87 billion (as of August 27, 2026)
Sector / Industry: Health care / Medical devices and diagnostics
Index membership: S&P 500
